悦康药业(688658.SH)子公司YKYY018雾化吸入剂获得FDA临床试验批准

Core Insights - YKYY018 aerosol inhalation agent has received FDA approval for clinical trials aimed at preventing and treating respiratory syncytial virus (RSV) infections [1] - The product is developed by the company's subsidiary, leveraging a full-process AI platform, and is an international original membrane fusion inhibitor [1] - YKYY018 has a novel mechanism of action, specifically binding to the F protein's HR1 region of RSV, inhibiting viral fusion with host cells, thus providing both therapeutic and preventive effects [1] - The company holds core patent rights for YKYY018 and has exclusive global rights to the product [1]